Answering Oasis’s governance demands, and the shift to an audit-committee board (2026)
The contest was over who would reform, not what reform meant
What is peculiar about this confrontation is that the point at issue was not the content of governance reform but who would carry it out. The very same measure — handing the chair of the board to an outside director — was voted down by the founding family when the company proposed it, and dismissed by the company as “already implemented” when the shareholder proposed it. All three parties spoke of reform, and none could agree on whose hands would do it. It can be seen as a process in which the real task, restoring the trust the beni-koji affair had damaged, was displaced into an institutional argument about the choice of board structure.
The move to a company with an audit and supervisory committee closed the argument about the vessel, but the substance of oversight is left to how it is operated from here. So long as the shareholder register holds a leading investor with 13.74% of the voting rights and a founding family with about 30%, management will struggle for stability while lacking the confidence of either. How far President Toyoda’s administration, which speaks of dialogue, can turn both sides’ demands into real discipline remains to be seen. As a case for measuring how the governance of a founder-family company balances against outside eyes, it is still in progress.
Revenue and net margin, FY2021–FY2025
Revenue in ¥ bn (bars) and net margin in % (line), for the years around the decision. Shaded columns are FY2026 onwards — after it was taken.
Source: securities reports
Read the full dossier in Japanese →
The Japanese edition carries the complete record of this decision — the situation that forced it, the options weighed, what actually followed, and the sources behind every claim.
Other key decisions at Kobayashi Pharmaceutical
Yen amounts are converted at the average rate of each figure’s own year — not today’s rate; the revenue chart is shown in yen. Exchange rates & sources — the full ¥/US$ table →
Disclaimer
- This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
- Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
- Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
- Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
- Company names, logos and other marks belong to their respective owners.
Data API
Kobayashi Pharmaceutical’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.
Full specification →
| Method | Endpoint | Returns |
|---|---|---|
| GET | /api/companies.json | All companies |
| GET | /api/4967/manifest.json | Resource index |
| GET | /api/4967/history.json | History overview |
| GET | /api/4967/timeline.json | Chronology |
| GET | /api/decisions.json | All management decisions (index) |
| GET | /api/4967/decisions.json | Management decisions (index) |
| GET | /api/4967/decisions/{slug}.json | One decision (full dossier) |
| GET | /api/4967/executives.json | Executives |
| GET | /api/4967/shareholders.json | Major shareholders |
| GET | /api/4967/financials.json | Financial statements |
| GET | /api/4967/financials-longterm.json | Long-term results |
| GET | /api/4967/segments.json | Business segments |
| GET | /api/4967/regions.json | Sales by region |
| GET | /api/4967/workforce.json | Workforce |